Search

Search Results for "Eylea HD"

Phase 2/3 Clinical Trial Data for EYLEA HD<sup>®</sup> (aflibercept) Injection 8 mg for the Treatment of DME thumbnail

Phase 2/3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of DME

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Phase 3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of Wet
AMD thumbnail

Phase 3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Dosing Considerations with 8 mg Aflibercept thumbnail

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Switching Agents in DME thumbnail

Switching Agents in DME

Michael Javaheri, MD

96-Week Safety Data Revealed for 8 mg Aflibercept thumbnail

96-Week Safety Data Revealed for 8 mg Aflibercept

Christina Y. Weng, MD, MBA

Real-World Data for 8 mg Aflibercept thumbnail

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

Exploring DME Outcomes Based on Baseline Vision thumbnail

Exploring DME Outcomes Based on Baseline Vision

Diana V. Do, MD

Outcomes with 8 mg Aflibercept; Does Prior DME Treatment Matter? thumbnail

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Extension Data for High-Dose Aflibercept thumbnail

Extension Data for High-Dose Aflibercept

Diana Do, MD

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents thumbnail

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Switch Case: Faricimab to High-dose Aflibercept thumbnail

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

A Treatment Paradigm for Wet AMD thumbnail

A Treatment Paradigm for Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Innovations in AMD Therapy: Second-Generation Anti-VEGFs thumbnail

Innovations in AMD Therapy: Second-Generation Anti-VEGFs

I. Paul Singh, MD; and Carl D. Regillo, MD

FDA Issues CRL to Regeneron for Eylea HD Extended Dosing

Glaukos Submits NDA for Epi-On CLX Candidate

CE Certification for New Glaucoma Surgical Implant

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE

Philip Storey, MD; and Prof. Sobha Sivaprasad

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Ted Leng, MD; and Michael Klufas, MD

View More